EDP Biotech one of 17 companies pitching next week at SEBIO Investor & Partnering Forum

Knoxville’s EDP Biotech Corporation is one of 17 companies – and the only one from Tennessee – invited to pitch during the Southeast BIO (SEBIO) Investor & Partnering Forum scheduled next week in Coral Gables, FL.

“EDP Biotech is honored to be selected among all of the high-quality life science companies presenting at SEBIO 2019,” says Eric Mayer, the company’s Chief Executive Officer. “We are proud to represent the State of Tennessee and the cutting-edge technology being developed here, competing among companies from the biotech hubs like Research Triangle Park and larger metro areas like Atlanta and Miami. The selection validates all of the hard work and recent traction made by EDP Biotech’s team, opening new doors to active, early stage life science investors and potential strategic partners from the southeast region.”

For the company that is bringing to market its ColoPlex™ product to detect colorectal cancer at the earliest possible time, the conference is clearly a significant opportunity. More than 300 biotech and medtech investors, corporate executives, university representatives, and entrepreneurs are expected to be in attendance.

As significant as the mix of attendees is, the results of being selected to pitch are just as meaningful if not more so. More than 220 later stage and 180 early stage companies that have participated in previous SEBIO Investor & Partnering Forums have raised more than $2.5 billion in public and private funding.

Regular readers of teknovation.biz know that we have followed the progress of the company and its ColoPlex™ product that is a blood-based test aimed at early detection of colorectal cancer and is seeking its first round of institutional investment.

On the first day of the event – November 6, EDP Biotech and the other invited early stage companies will participate in 40-minute individual private advisory sessions behind closed doors with teams of investors, business advisors, service providers and successful entrepreneurs. Four of the 17 will be selected to present to the full conference audience during the “Early Stage Competition” with an overall winner announced at the lunch on November 7.

The other companies invited to participate are:

  • Achelios Therapeutics, a Chapel Hill clinical-stage specialty pharmaceutical company developing proprietary topical formulations of non-steroidal anti-inflammatory drug molecules to treat pain and inflammation;
  • AMPEL Biosolutions, a Charlottesville technology company with Clinical Research Organization capabilities combining genomic technologies with advanced analytics to develop the Clinical Genomic Blood Test to match patients to the best therapy in clinical trials and clinical care;
  • Ares Immunotherapy, a pre-clinical adoptive T cell therapy company located in Atlanta and based on technology discovered at the Medical University of South Carolina that is developing CD26+ CAR-T cells therapy specific for mesothelin for the treatment of mesothelioma and other solid tumors;
  • Azure 8, another Atlanta-based medical device company developing the Sonix-A8TM, a Class II medical device to prevent and control surgical site and catheter-related bacterial infections;
  • Cathaid, an Augusta, GA medical device company developing CathaidTM, a Class I medical device to better secure central venous catheters which allows real time detection of dangerous positional shifts and reduces infection;
  • Dermasensor, a medical device company from the local (Miami) area that is developing a handheld wireless medical device for dermatologists that uses electron scattering microscopy combined with a proprietary algorithm to evaluate skin lesions for potential skin cancer;
  • Evren Technologies, also located in Florida that is commercializing a wearable device that provides transcutaneous vagal nerve stimulation for the treatment of post-traumatic stress disorder;
  • IMMvention Therapeutix, a drug discovery start-up based on technology discovered at the University of North Carolina, Chapel Hill that is developing a pre-clinical pipeline of proprietary innate immunity specific therapies for autoimmune and inflammatory diseases;
  • Inquisatex Epitherapeutics, a Charleston, SC drug discovery start-up that is developing a novel series of compounds for the treatment of Sickle Cell Disease based on technology discovered at the Medical University of South Carolina;
  • KeViRx, a pre-clinical oncology company based on technology discovered at the University of Virginia and the University of Pittsburgh that is developing KVR-053, an allosteric PTP4A3 phosphatase small molecule inhibitor for ovarian, colorectal and breast cancers;
  • Oracle Health, a medical device company located in Tampa and developing a digital health-enabled Insertable Cardiac Monitor (ICM) to follow heart failure progression and prevent heart failure hospitalization; \
  • Oxidien Pharmaceuticals, another Florida-based start-up clinical stage drug development company with proprietary enzyme assets to treat hyperoxaluria, a severe and debilitating condition causing renal damage, progressive chronic kidney disease, and end-stage renal failure;
  • Park Surgical Innovations, an Atlanta medical device company developing the Park Surgical Graft Delivery System, a class II medical device and method for delivering a prosthetic graft for laparoscopic ventral hernia repair;
  • Plakous Therapeutics, a Winstom-Salem pre-clinical regenerative medicine company developing Protego-PD™, an acellular placental derived platform product for the treatment of necrotizing enterocolitis and osteoarthritis; and
  • Pyrefin Inc., another Atlanta pre-clinical drug discovery company based on technology discovered at Emory University that is developing orally-active small molecule antagonists of the prostaglandin E2 receptor for the treatment of pain and inflammation.

Stay connected with us on Twitter and LinkedIn. Article ideas and other suggestions should be sent to tballard@pyapc.com. Include the name and contact information (phone and email) for follow-up.